How External Control Arms and Real-World Data Are Driving Clinical Trial Innovation

Clinical research is evolving, along with the methodologies used to evaluate the safety and efficacy of new therapies. Traditional randomized controlled trials (RCTs) remain the gold standard in clinical research, but can drive ethical concerns and operational challenges, prompting a need for innovative alternatives. One of those alternatives is external control arms (ECAs), which leverage real-world data (RWD) to optimize trial efficiency and accelerate drug development.

The Benefits of External Control Arms

External control arms utilize other data sources, such as RWD, to construct comparator groups, reducing or even eliminating the need for placebo or standard-of-care control arms. This approach is particularly beneficial in rare or complex conditions. Recruiting control-arm patients in these settings can be extremely difficult, leading to small sample sizes and potential biases in single-arm trials. ECAs help provide meaningful comparative insights.

The construction of effective ECAs has the potential benefit in clinical research across multiple facets, such as:

• Addressing ethical concerns: In life-threatening conditions or areas with no clear standard of care, it may be unethical to assign patients to a placebo. ECAs offer a robust alternative, ensuring that all participants receive active treatment. Likewise, reducing reliance on non-interventional groups can help make research more patient centered.
• Accelerated development timelines: By reducing the need to recruit and randomize control-arm patients, ECAs have the potential to shorten trial durations and expedite regulatory submissions.
• Enhancing trial generalizability: With RWD drawn from diverse patient populations and geographies, ECAs can help improve the generalizability and diversity of clinical trial results.

Verana Health: A Leader in Real-World Data for External Control Arms

Verana Health is at the forefront of RWD-driven clinical research, providing high-quality, curated datasets to support external control arms. Through exclusive partnerships with the American Academy of Ophthalmology IRIS^® Registry (Intelligent Research in Sight) and the American Urological Association (AUA) Quality (AQUA)^® Registry, Verana Health has access to an RWD network of more than 90 million de-identified patients, enabling robust and regulatory-grade ECAs. By ingesting and curating this electronic health record data and applying artificial intelligence techniques, such as machine learning and natural language processing, Verana Health delivers:

• High-quality Qdata^® – research-ready datasets that allow life sciences companies to readily access potential control arm data to accelerate clinical development timelines.
• Support for complex conditions: From ophthalmic diseases, such as retinitis pigmentosa, to challenging oncology indications, Verana Health ensures ECAs are backed by comprehensive, fit-for-purpose data.

The Future of ECAs and Clinical Research

Regulatory agencies, including the FDA, are increasingly receptive to RWD-based ECAs, recognizing their value in modern clinical development. As regulatory frameworks evolve, Verana Health continues to align its methodologies with the highest scientific standards, ensuring that life sciences companies can confidently integrate ECAs into their study designs.

By addressing potential ethical challenges, enhancing trial diversity, and expediting time-to-market for critical therapies, ECAs are poised to transform clinical research. Verana Health stands ready to support this shift, pioneering data-driven innovation to bring life-changing treatments to patients faster and more efficiently.

To view recent studies that demonstrate the potential of ECAs, read our white paper.